FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, namely to a method for preparing an anticancer vaccine agent for treating solid tumours. The method for preparing the anticancer vaccine agent for treating solid tumours consisting in sampling of a raw tumour material, mixing and homogenisation in a buffer solution, multiple centrifugation with residue sampled; the residue is suspended in an acid buffer, mixed, neutralised, centrifuged; the supernatant is collected, enriched and purified with a combination of salt deposition and chromatography on an immobilised protein A or G; the prepared solution is passed through columns with immobilised human immunoglobulins IgG and human placental immobilised proteins; the prepared antibodies are subject to enzymatic treatment to prepare Fab- or F(ab)2-fragments used to immunise animals; immune antibodies are prepared and used to recover the total immunoglobulin fraction to be passed through the columns with the immobilised human immunoglobulins IgG and immobilised human placental proteins; the solution passed through the columns is subject to immunoaffinity chromatography on the columns with immobilised immunoglobulins prepared earlier at the stage of purification and enrichment; the end products specifically bound by the latter types of the columns are eluted with a solution dissociating antigen-antibody complexes, concentrated, filtered through antimicrobial filters, mixed with an adjuvant.
EFFECT: preparation prepared by the method described above enables providing higher clinical effectiveness in solid tumours treatment.
2 ex
